DRL launches Clofarbine injection in US Markets

Dr. Reddy s Laboratories Ltd has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar (clofarabine) Injection in the United States market. The company has earlier received USFDA approval for the drug. The drug is a generic version of the injection is available in single-dose, 20 ml flint vials containing 20 mg of clofarabine in 20 ml of solution (1mg/mL). The Clolar brand and its generic had U.S. sales of approximately USD 53 million MAT (Moving Annual Total) for the most recent twelve months ended in September 2017, according to industry estimates. Clofarabine Injection is used to treat acute Lymphoblastic Leukemia, a cancer of white blood cells.

Company Profile : Dr Reddys Laboratories Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.